IDT Australia (ASX:IDT) EBITDA Margin %: -3.77% (As of Dec. 2025)


What is IDT Australia EBITDA Margin %?

IDT Australia ASX:IDT EBITDA Margin % is -3.77% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, IDT Australia ranks worse than 84.5% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. IDT Australia's EBITDA for the six months ended in Dec. 2025 was A$-0.37 Mil. IDT Australia's Revenue for the six months ended in Dec. 2025 was A$9.72 Mil. Therefore, IDT Australia's EBITDA margin for the quarter that ended in Dec. 2025 was -3.77%.


IDT Australia  (ASX:IDT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


IDT Australia EBITDA Margin % Related Terms


IDT Australia EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for IDT Australia's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDT Australia EBITDA Margin % Chart

IDT Australia Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.52 -3.02 -127.38 -38.04 -33.53

IDT Australia Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.48 -19.36 -31.24 -36.10 -3.77

ASX:IDT vs ZTS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDT Australia EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, IDT Australia's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where IDT Australia's EBITDA Margin % falls into.



IDT Australia EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

IDT Australia's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-6.443/19.217
=-33.53 %

IDT Australia's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.367/9.723
=-3.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -3.77% mean?
IDT Australia (ASX:IDT) has a EBITDA Margin % of -3.77% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IDT Australia and its competitors. According to the industry distribution chart, IDT Australia ranks #807 out of 955 companies in the Drug Manufacturers industry, placing it in the top 84.5%.
Is IDT Australia's EBITDA Margin % too high?
IDT Australia's current EBITDA Margin % is -3.77%. Based on the distribution chart, IDT Australia ranks #807 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does IDT Australia's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, IDT Australia ranks #807 out of 955 companies for EBITDA Margin %. This places IDT Australia in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IDT Australia and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDT Australia's current EBITDA Margin % is -3.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.17, compared to a current price of A$0.03 — trading 80.6% below its estimated fair value. The current EBITDA Margin % is -3.77%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current EBITDA Margin % is -3.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IDT Australia Business Description

Address 45 Wadhurst Drive, Boronia, Melbourne, VIC, AUS, 3155
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.